News
Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to ...
Key Points Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is ...
Novo Nordisk is partnering with WeightWatchers to offer consumers access to Wegovy after it abruptly ended its collaboration with Hims & Hers.
The partnership has been terminated less than two months after launch as Novo Nordisk alleges Hims & Hers is illegally selling copycat drugs and using deceptive marketing practices.
Hims & Hers stock fell 35% after Novo Nordisk ended their partnership on Monday. Novo Nordisk stopped the deal because Hims sold a cheaper version of Wegovy.
Novo Nordisk ends collaboration with Hims & Hers for discounted weight loss meds Novo Nordisk and Hims & Hers just announced a partnership in April.
Novo Nordisk has cut ties with Hims & Hers Health, alleging that the latter company has engaged in deceptive marketing tactics and illegal compounding, risking patient safety.Novo Nordisk ...
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.
Hims & Hers stock plunged 30% on Monday after Novo Nordisk abruptly ended a collaboration to offer direct access to its weight loss drug Wegovy.
Novo Nordisk said it's ending its collaboration due to concerns with Hims & Hers the company's sales and promotion of cheap knock-offs of the weight loss drug Wegovy, it said on Monday.
This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results